gp63 homologues in Trypanosoma cruzi: surface antigens with metalloprotease activity and a possible role in host cell infection.

نویسندگان

  • Ileana C Cuevas
  • Juan J Cazzulo
  • Daniel O Sánchez
چکیده

gp63 is a highly abundant glycosylphosphatidylinositol (GPI)-anchored membrane protein expressed predominantly in the promastigote but also in the amastigote stage of Leishmania species. In Leishmania spp., gp63 has been implicated in a number of steps in establishment of infection. Here we demonstrate that Trypanosoma cruzi, the etiological agent of Chagas' disease, has a family of gp63 genes composed of multiple groups. Two of these groups, Tcgp63-I and -II, are present as high-copy-number genes. The genomic organization and mRNA expression pattern were specific for each group. Tcgp63-I was widely expressed, while the Tcgp63-II group was scarcely detected in Northern blots, even though it is well represented in the T. cruzi genome. Western blots using sera directed against a synthetic peptide indicated that the Tcgp63-I group produced proteins of approximately 78 kDa, differentially expressed during the life cycle. Immunofluorescence staining and phosphatidylinositol-specific phospholipase C digestion confirmed that Tcgp63-I group members are surface proteins bound to the membrane by a GPI anchor. We also demonstrate the presence of metalloprotease activity which is attributable, at least in part, to Tcgp63-I group. Since antibodies against Tcgp63-I partially blocked infection of Vero cells by trypomastigotes, a possible role for this group in infection is suggested.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Trypanosoma cruzi GP63 proteins undergo stage-specific differential posttranslational modification and are important for host cell infection.

The protozoan Trypanosoma cruzi expresses multiple isoforms of the GP63 family of metalloproteases. Polyclonal antiserum against recombinant GP63 of T. cruzi (TcGP63) was used to study TcGP63 expression and localization in this organism. Western blot analysis revealed that TcGP63 is 61 kDa in epimastigotes, amastigotes, and tissue culture-derived trypomastigotes but 55 kDa in metacyclic trypoma...

متن کامل

Trypanocidal activity of some endemic species of Satureja in Iran

Trypanosoma cruzi, a hemoflagellate protozoan (family Trypanosomatidae), is the ethiological agent of Chagas disease, which is affecting 16-18 million people, with more than 100 million exposed to the risk of infection. Higher plants are a potential source of new drugs to improve the treatment of Chagase disease. Until recently, Rutacea, Meliaceae, Simaroubaceae and Burceraceae families have be...

متن کامل

Effects of some fractions from Achillea biebersteinii and A.millefolium on the epimastigotes of Trypanosoma cruzi

Higher plants are a potential source of new drugs to improve the treatment of Chagase disease, which is affecting 16-18 million people, with more than 100 million exposed to the risk of infection (Ambrozin et al., 2004; Coura & Castro, 2002). Current therapy is unsatisfactory, because the only two drugs available, benznidazole and nifortimox possess severe side effects and their activity is lim...

متن کامل

Expression and function of the Trypanosoma brucei major surface protease (GP63) genes.

The genome of the African trypanosome Trypanosoma brucei (Tb) contains at least three gene families (TbMSP-A, -B, and -C) encoding homologues of the abundant major surface protease (MSP, previously called GP63), which is found in all Leishmania species. TbMSP-B mRNA occurs in both procyclic and bloodstream trypanosomes, whereas TbMSP-A and -C mRNAs are detected only in bloodstream organisms. RN...

متن کامل

Effects of some fractions from Achillea biebersteinii and A.millefolium on the epimastigotes of Trypanosoma cruzi

Higher plants are a potential source of new drugs to improve the treatment of Chagase disease, which is affecting 16-18 million people, with more than 100 million exposed to the risk of infection (Ambrozin et al., 2004; Coura & Castro, 2002). Current therapy is unsatisfactory, because the only two drugs available, benznidazole and nifortimox possess severe side effects and their activity is lim...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Infection and immunity

دوره 71 10  شماره 

صفحات  -

تاریخ انتشار 2003